Abstract |
A patient with aggressive, chemotherapy-resistant non-Hodgkins lymphoma (NHL) was treated with 131I-Lym-1, a mouse antibody, on a protocol designed for serial therapy. Human anti-mouse antibody (HAMA) developed within 1 month of initial therapy. The patient also developed an antibody to the hypervariable region of the Lym-1 antibody (Lym-1 specific). Because the patient was responding to therapy, plasmaphoresis was used to reduce the level of HAMA followed by unlabeled Lym-1 calculated to be sufficient to block residual HAMA. This allowed additional therapy on three subsequent occasions over 5 months. Despite very high HAMA levels, no untoward effects from administrations of Lym-1 were observed. The HAMA response of the patient included anti-Lym-1 specific antibodies containing anti-idiotypic antibodies. The anti-Lym-1 antibody level has been sustained over the 9 year interval since 131I-Lym-1 therapy and has been associated with a uniquely long remission of the patient's disease. These observations demonstrate that, under certain circumstances, radioimmunotherapy (RIT) can be given safely and effectively despite HAMA. Anti-idiotypic antibodies could have induced an immune cascade that contributed to the prolonged disease-free survival of the patient.
|
Authors | S J DeNardo, L A Kroger, M R MacKenzie, G R Mirick, S Shen, G L DeNardo |
Journal | Cancer biotherapy & radiopharmaceuticals
(Cancer Biother Radiopharm)
Vol. 13
Issue 1
Pg. 1-12
(Feb 1998)
ISSN: 1084-9785 [Print] United States |
PMID | 10850337
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Iodine Radioisotopes
- Lym-1 monoclonal antibody
- Radiopharmaceuticals
|
Topics |
- Animals
- Antibodies, Anti-Idiotypic
(blood)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, immunology, pathology, radiotherapy)
- Mice
- Middle Aged
- Radioimmunotherapy
- Radiopharmaceuticals
(therapeutic use)
- Recurrence
|